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In combination with whole-cell biotransformations,t hese stereocomplementary biocatalysts enabled the multigram synthesis of the chiral cyclopropane core of four drugs (Tranylcypromine,T asimelteon, Ticagrelor,a nd aT RPV1 inhibitor) in high yield and with excellent diastereo-and enantioselectivity (98-99.9% de;9 6-99.9% ee). These biocatalytic strategies outperform currently available methods to produce these drugs.
Catalytic methods for the cyclopropanation of olefins cover aprominent role in organic and medicinal chemistry owing to the recurrence of cyclopropanem otifs among biologically active natural products and pharmaceuticals. [1] Significant progress has been made in the development of synthetic methods for asymmetric cyclopropanation, in particular through the transition-metal-catalyzed insertion of carbenoid species into carbon-carbon double bonds.
[2] More recently, the Arnold group and our own laboratory have shown that engineered cytochrome P450s [3] and myoglobins (Mb), [4] respectively,c onstitute promising catalysts for mediating the cyclopropanation of styrenes in the presence of a-diazoacetate reagents,thus providing abiocatalytic alternative for this valuable transformation. Va riants of the bacterial cytochrome P450 BM3 were found to favor cis selectivity in the cyclopropanation of styrene in the presence of ethyl a-diazoacetate (EDA; P450 BM3 -CIS-T438S:86%de (cis), 97 % ee (1S,2R)).
[3a]
By utilizing ad ifferent P450 enzyme,o pposite enantioselectivity was achieved by Brustad and co-workers for the cis cyclopropanation of this substrate,a lbeit with more moderate diastereoselectivity (P450 Biol -T238A:4 2% de (cis), 95 % ee (1R,2S)). [5] Unfortunately,v arying cis/trans ratios and degrees of stereoselectivity were observed with these enzymes in the presence of other styrene derivatives. [3a, 5] We previously reported the development of an engineered myoglobin variant, Mb(H64V,V68A), that is capable of catalyzing the cyclopropanation of styrene with EDAw ith excellent trans diastereoselectivity and (1S,2S) enantioselectivity (99.9 % de,9 9.9 % ee).
[4] Promisingly,t he high trans-(1S,2S)s electivity of this Mb variant extended to the cyclopropanation of av ariety of styrene derivatives (97-99.9 % de,9 6-99.9 % ee). [4] Thea bility to access both enantiomeric forms of at arget cyclopropane pharmacophore is critical in the context of the synthesis of bioactive molecules,a ss uch stereoisomers often exhibit remarkably divergent pharmacological and/or toxicity profiles. [1] However,d eveloping stereo-or enantiocomplementary variants of an enzyme is far from being at rivial task, [6] as mirror-image forms of these biomolecules are not readily available. [7] Reflecting this notion, cyclopropanation biocatalysts that can reliably offer complementary stereoselectivity have thus far remained unavailable. [3, 5, 8] Herein, we report the development and characterization of ap anel of engineered Mb catalysts that provide access to trans-(1R,2R)-configured 1-carboxy-2-aryl-cyclopropanes with high selectivity and catalytic activity across ab road range of olefin substrates.W ef urther demonstrate that these Mb-catalyzed reactions can be carried out and scaled up using whole-cell systems.U sing these stereocomplementary biocatalysts in combination with whole-cell transformations,the asymmetric synthesis of the cyclopropane core of four different drugs, featuring both trans-(1S,2S)and trans-(1R,2R)configurations, was accomplished at the multigram scale.
Previously,wefound that mutations at the five amino acid positions defining the distal pocket in Mb (i.e., Leu29, Phe43, His64, Va l68, and Ile107;s ee the Supporting Information, Figure S1 ) significantly affected the activity and selectivity of this hemoprotein in carbene [4, 9] and nitrene [10] transfer reactions.I np articular,m utation of the distal histidine residue (H64V) was shown to have ag eneral activityenhancing effect in these reactions,p ossibly owing to an increased accessibility of the heme pocket to the reactants. This mutation also slightly increases the trans-(1S,2S)s electivity of Mb for styrene cyclopropanation with EDA(93 % de (trans), 10 % ee (1S,2S)c ompared to 86 % de (trans), 6% ee (1S,2S)for wild-type Mb). This effect could be combined with that of astronger trans-(1S,2S)selectivity inducing mutation, i.e., V68A (96 % de (trans), 68 % ee (1S,2S)), to yield the aforementioned highly trans-(1S,2S)-selective Mb(H64V,V68A) catalyst ( Figure 1 , gray path). [4] These results supported our hypothesis that additive effects can be leveraged to fine-tune the stereoselectivity of Mb in cyclopropanation reactions.A tt he same time,n one of the activesite Mb variants (> 10) examined in these earlier studies showed any preference for formation of the trans-(1R,2R) product, indicating that achieving this type of stereoselectivity would require exploration of aw ider active-site sequence space.O nt he basis of these considerations,w es ought to implement as ystematic active-site mutagenesis approach combined with structure-reactivity-guidedd esign to achieve our goal of developing trans-(1R,2R)-selective Mb catalysts. Accordingly,s tarting from Mb(H64V) as the parent protein, each of the remaining four active-site positions was systematically mutated to any of the other 19 amino acids by site-directed mutagenesis.This process resulted in alibrary of 76 Mb(H64V)-derived variants,w hich were tested individually for their activity (turnover number, TON) and selectivity in the model cyclopropanation reaction with styrene and EDA ( Table S2 ). Nearly half of these Mb variants (33/76; 43 %) could be expressed in E. coli in correctly folded form as determined by the signature Soret band for their CO-bound complex (l max % 420 nm). Moreover,t he large majority of these proteins (75 %) was catalytically competent (TON > 50) towards styrene cyclopropanation (Table S2) , highlighting the robustness of the Mb active site to mutagenesis.M ore importantly,s creening of the library led to the identification of an umber of Mb variants with significantly improved trans-(1R,2R)s electivity (Table 1 ) compared to the parent protein Mb(H64V) or wild-type Mb.M ost effective in favoring such selectivity was the introduction of al eucine or phenylalanine residue in place of Va l68 (i.e., 86!99 % de, (À6)!70-72 % ee (1R,2R)). Residue 68 lies along the side of the heme group and is expected to be in close proximity to the putative heme-bound carbene intermediate implicated in the cyclopropanation reaction. [4] Interestingly,substitution of the more remote Leu29 with either serine or threonine was also beneficial towards enhancing trans-(1R,2R)s electivity,a s indicated by the 93-95 % de and 59-70 % ee values obtained with Mb(L29S,H64V) and Mb(L29T,H64V) ( Table 1) . Mutations of positions Phe43 or Ile107 had noticeable but comparatively weaker effects on favoring trans-(1R,2R) selectivity (16-55 % ee;T able S2). Moreover,anumber of highly trans-(1S,2S)-selective variants were identified among the Va l68 site-saturation sub-library,i ncluding Mb(H64V,V68S) and Mb(H64V,V68C), which produce 3b in > 99 % de and ee (Tables 1a nd S2) .
To obtain Mb catalysts with further improved trans-(1R,2R)s electivity,t he beneficial mutations at position 68 (V68L, V68F) were combined with those at position 29 (L29T,L 29S) and 107 (I107 H) to yield as et of triple-site variants (Table S3) . Gratifyingly,t his process resulted in the identification of two closely related variants, Mb(L29T,H64V,V68L) and Mb(L29T,H64V,V68F), with excellent trans diastereoselectivity (99 % de)a long with high 1R,2R stereoselectivity (92 % ee;T able 1). Next, these Mb variants were further mutated at position Ile107 or Phe43, with the choice of the target substitutions being guided by the structure-reactivity relationship (SRR) data collected during screening of the initial library.Although none of the resulting quadruple-site variants with substitutions at position 107 showed improved trans-(1R,2R)s electivity,t he introduction of the F43W mutation in the Mb(L29T,H64V,V68F) background led to the desired additivity effect. Indeed, the corresponding Mb(L29T,F43W,H64V,V68F) variant catalyzes the transformation of styrene and EDAinto 3a with excellent diastereo-and enantioselectivity (> 99 % de,9 5% ee; Table 1 ). It should be noted that refinement of the trans-(1R,2R)selectivity came with no loss in catalytic efficiency as indicated by the comparable TONs achieved with the trans-(1R,2R)-selective Mb variants and the parent protein (265-460 vs.2 35 TON). Figure 1p rovides ag raphical representa- Figure 1 . Structure-reactivity-guided design of Mb cyclopropanation biocatalysts with complementarystereoselectivity.T he path in gray is described in Ref. [4] . Table 2 , quantitative product conversion (95-99 %) was achieved with different para-, meta-, ortho-, and alpha-functionalized styrenes (4b-6b, 8b-10 b), with more moderate conversion (45 %) being observed only with 4-trifluoromethylstyrene (product 7b). Importantly,f or all of these substrates,t he desired trans-(1R,2R)-configured cyclopropane products were obtained with good to excellent diastereoselectivity (92-99 % de)and enantioselectivity (49-99 % ee)with one or more of the Mb variants.Next, we extended these analyses to other aryl-substituted olefins,i ncluding pyridine,t hiophene, N-methylimidazole,a nd benzothiazole derivatives.T hese molecules comprise N-and S-containing heterocycles,w hich are notoriously problematic in the context of cyclopropanation reactions with rhodium-or other metal-based complexes owing to catalyst poisoning effects.F or example,the reaction of 1-methyl-2-vinylimidazole with EDAa nd Rh 2 (OAc) 4 as the catalyst failed to give any product (see the Supporting Information for details). Notably,all of these olefins could be efficiently processed by the engineered Mb catalysts,resulting in product conversions of up to 84 %( 11 b-15 b,T able 2). Furthermore,t he corresponding trans-(1R,2R)c yclopropane products could be obtained with good to very good selectivities (65-99 % de,6 5-98 % ee). Fora ll of these transformations,c omplementary stereoselectivity is provided by the trans-(1S,2S)-selective Mb(H64V,V68A) variant (Table S4) .
Whole-cell biotransformations constitute ac onvenient approach to enhance the scalability of biocatalytic processes supported by heme-dependent enzymes.
[3b, 11] Importantly,we established that the Mb(H64V,V68A)-catalyzed cyclopropanation of styrene with EDAtogive 3bcan be readily achieved using E. coli cells (BL21DE3) expressing this Mb variant, resulting in high product conversion (68-100 %) even under aerobic conditions (Table S5) . Furthermore,t he substrate loading in these whole-cell reactions could be increased up to 0.5 m styrene and 0.5 m EDAi na1:1 ratio while maintaining high conversion (62 %) and excellent selectivity (99.9 % de, 99.9 % ee;T able S5).
Aryl-substituted trans cyclopropanes are found in several marketed and investigational drugs (Scheme 1), [1] including the MAOi nhibitor Tr anylcypromine ((AE)-16,f ormerly Parnate), [12] the melatonin receptor agonist Tasimelteon (20), [13] the TRPV1 antagonist 24, [14] and the platelet aggregation inhibitor Ticagrelor (28,B rilinta). [15] Although Tr anylcypromine has been used in clinical settings in racemic form, the two enantiomers display different biological potencies. [16] The other drugs are used in enantiomerically pure form. Each of these molecules features ac yclopropane unit that can be retrosynthetically derived from either a trans-(1R,2R)-((À)-16, 19, 28)ortrans-(1S,2S)-configured 1-carboxy-2-aryl-cyclopropane ((+ +)-16, 24). As such, these drugs were chosen as relevant targets to assess the synthetic utility of the stereocomplementary cyclopropanation biocatalysts developed herein.
Accordingly,toobtain the dextrorotatory form of Tr anylcypromine,alarge-scale reaction with E. coli cells expressing Mb(H64,V68A) was carried out in the presence of 2.9 g styrene and 3.1 gEDA (1 equiv), resulting in the isolation of 3b as the only product (99.9 % de,9 9.9 % ee)i n9 1% yield (4.7 g; Scheme 1a). Under similar reaction conditions,b ut using cells expressing Mb(L29T,H64V,V68L), 1.2 go ft he opposite enantiomer 3a were obtained in 80 %y ield and excellent selectivity (99.9 % de,95% ee). Both intermediates can be converted into the desired (+ +)-and (À)-Tranylcypromine,respectively,byconversion into the corresponding acyl 
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Communications azides followed by astereoretentive Curtius rearrangement [16] and hydrolysis (93 %yield over three steps for (+ +)-16;see the Supporting Information for details). By comparison, the same cyclopropanation reaction catalyzed by two prominent Cu(Box) catalysts was reported to proceed with high stereoselectivity (90-99 % ee)b ut only moderate diastereoselectivity (46-50 % de (trans)).
[2d,e]
Thea symmetric cyclopropanation of olefin 18 to give 19 represents ak ey step in the synthesis of Tasimelteon as reported by chemists at Bristol-Myers Squibb. [17] Under best performing conditions,t his transformation was realized in 91 % de and 85 % ee using NishiyamasR u(iPr-PyBox) catalyst in the presence of excess EDA. After affording olefin intermediate 18 according to published procedures, [17] this compound was subjected to Mb-catalyzed cyclopropanation using whole cells expressing the trans-(1R,2R)-selective variant Mb(L29T,H64V,V68F,I107L) in the presence of stoichiometric amounts of EDA( Scheme 1b). Notably,t he desired 1R,2R-configured cyclopropanation product 19 was obtained in 99.9 % de and 96 % ee and in 91 %isolated yield (0.96 g), thus furnishing ak ey intermediate en route to Tasimelteon (20). [17] Thes tereoselective cyclopropanation of 22 into 23 was denoted by Pfizer chemists as "the most challenging step" in the preparation of the advanced drug candidate 24, [14] owing to the presence of apyridine functional group and formation of at risubstituted cyclopropane.
[2k] Upon screening over 120 different catalytic conditions,t he best results were obtained using Ru(iPr-PyBox) as the catalyst to give 23 in 40 % de and 65 % ee. [14] Using whole cells expressing Mb(H64V,V68A), 0.83 gof23 could be obtained in high yield (75 %) with much greater diastereo-and enantioselectivity (99.9 % de,9 9.9 % ee;S cheme 1c). Thec yclopropanation product was further processed to afford 24 (see the Supporting Information for details).
Lastly,w et argeted the synthesis of (1R,2R)-ethyl 2-(3,4-difluorophenyl)cyclopropanecarboxylate 26 (Scheme 1d), which can be readily hydrolyzed to 27,akey synthetic intermediate for the preparation of Ticagrelor. [15] Of note,this intermediate is currently accessible through synthetic routes involving no less than four to five steps. [15, 18] Conveniently,the key cyclopropane building block 26 could be obtained in as ingle step in high yield (94 %) and selectivity (98 % de, 58 % ee)b yw hole-cell cyclopropanation of commercially available 3,4-difluorostyrene with cells expressing the (1R,2R)-selective Mb(L29T,H64V,V68L) variant. Taken together,these results demonstrate the promise and scalability of stereoselective myoglobin-catalyzed cyclopropanations in the context of relevant and challenging building blocks for drug synthesis.
In summary,w eh ave reported the successful design and application of myoglobin-based cyclopropanation biocatalysts that are capable of offering high trans selectivity along with complementary stereoselectivity across abroad panel of aryl-substituted olefins.F urthermore,w eh ave demonstrated that these myoglobin-mediated transformations can be performed in the context of whole-cell systems,w hich further simplifies their use for synthetic applications.The biocatalytic systems developed here have enabled the stereoselective synthesis of multiple cyclopropane-containing drugs at the preparative scale,o ffering superior performance over currently available methods for asymmetric cyclopropanation (i.e., (+)-and (À)-16, 20,and 24)orgranting amore concise route to their preparation (28). Along with the growing number of abiotic reactions accessible using engineered myoglobins, [4, 9, 10, 19] these results support the promise of these metalloproteins for the asymmetric synthesis of chiral drugs and synthons at apractical scale.
